Protagonist Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2026-04-16 EDT			5-day change	1st Jan Change
103.73 ^USD	-1.62%		-0.34%	+18.77%

04-15	Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating	MT
03-30	Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing	MT

Published on 03/03/2025 at 08:30 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and welcome to the Protagonist Therapeutics March 3 Conference Call. [Operator Instructions] As a reminder, this call is being recorded

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

04-15	Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating	MT
03-30	Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing	MT
03-30	Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing	MT
03-26	Protagonist Therapeutics Insider Sold Shares Worth $5,524,700, According to a Recent SEC Filing	MT
03-19	Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says	MT
03-19	Wedbush Raises Price Target on Protagonist Therapeutics to $112 From $100, Keeps Outperform Rating	MT
03-18	Protagonist Therapeutics, Inc. - Special Call
03-18	Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis -- Update	DJ
03-18	Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis	DJ
03-18	Johnson & Johnson Gets FDA OK for Icotyde in Plaque Psoriasis	DJ
03-18	Johnson & Johnson Says Icotyde Approved by FDA to Treat Plaque Psoriasis	MT
03-18	US FDA approves J&J's oral psoriasis pill	RE
03-12	Protagonist Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 11:30 AM
03-02	Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera	CI
03-02	Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating	MT